We conducted a systematic literature review to explore the association between circulating C-reactive protein (CRP), a low-grade inflammation biomarker, and breast cancer risk. Relevant prospective studies in women were identified in PubMed and Web of Science until February 2015. Random-effects dose-response metaanalysis was conducted, overall and in post-menopausal women. Twelve out of 15 studies identified were included in the meta-analysis on any breast cancers (3,522 cases, 69,610 women) and nine on postmenopausal breast cancer (2,516 cases, 36,847 women). For each doubling of CRP concentration, a 7% (95% CI: 2%-12%) and 6% (95% CI: 1%-11%) increased risk was observed (I 2 =47% and 32%; P heterogeneity=0.04 and 0.17), respectively. The association was linear over most of the range of CRP concentrations. Positive associations remained in the studies that examined the exclusion of early years of follow-up. Associations were attenuated in studies adjusted for lifestyle factors, which partly explained the significant heterogeneity between studies in the overall analysis. On average, the associations in studies adjusted or not adjusted for body mass index were similar.
Introduction
Several studies have explored the intricate association between chronic inflammation and cancer, but whether chronic inflammation has a causal role in cancer pathogenesis, or is simply a marker of the disease is unclear. Indeed, some cancers arise at sites of chronic inflammation, while other cancers induce an inflammatory microenvironment (1) . C-reactive protein (CRP) is a sensitive, non-specific biomarker of inflammation that is produced in the liver. Circulating CRP level is acutely elevated in response to proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-6) following an infection or tissue damage, and moderately elevated in the state of low-grade inflammation (1) . High-sensitive assay methods with detection limits of <0.3 mg/L can readily measure lower concentrations of CRP in blood (2) .
CRP levels have been shown to increase with obesity (3), smoking (4), post-menopausal hormone use (5), and to be lower with higher physical activity levels (6) , better diet quality (7) , and higher alcohol intake (8) .
Obesity-induced inflammation is associated with upregulation of proinflammatory cytokines, which promote neoplasia and tumour progression (9) . Chronic inflammation is also linked directly to tumour initiation and promotion, through the production of reactive oxygen species and reactive nitrogen species that induce genomic instability and DNA damage (10) .
Increased concentration of CRP is associated with increased risk of cardiovascular diseases and mortality (11) , colorectal cancer (12) and lung cancer (13) . Poorer prognosis in cancer patients, including those of breast cancer was also reported (1, 14) , but evidence on the association of CRP with breast cancer risk is inconsistent. The association may also differ by degree of body adiposity. Stronger positive associations in overweight and obese women than in normal weight women were reported by a recent hospital-based casecontrol study (15) , although reverse causation (inflammatory processes induced by occult cancer) could have influenced the results in this study.
In 2013, a meta-analysis of six prospective studies reported a non-significant positive association of CRP concentration and breast cancer risk, with moderate heterogeneity between studies (16) . Since then, six more large-scale prospective studies (17) (18) (19) (20) (21) (22) [three American (18) (19) (20) , two French (17, 21) , and one Chinese (22) studies] have been published, adding 2,038 cases and 27,968 study participants to the evidence.
Hence, we conducted an updated systematic review and meta-analysis to investigate whether circulating CRP, a biomarker of chronic inflammation, is a risk factor for breast cancer development. We based the review on prospective studies because in these studies blood samples were collected before breast cancer diagnosis. We further examined the association in relation to possible biases from reverse causation, confounding, and effect modification by body adiposity.
Materials and Methods
A PRISMA checklist (23) of the items reported in this review is provided in Supplementary Methods and Materials 1.
Data sources and search
We searched systematically in PubMed and Web of Science (databases: MEDLINE, Web of Science Core Collection, CAB Abstracts, Current Contents Connect, and Journal Citation Reports) for articles on circulating CRP and breast cancer in humans, that were published on any language from database inception to February 2015. The search strategy contained medical subject headings and/or variants of text words on CRP and breast cancer (Supplementary Methods and Materials 2). We also hand-searched the reference lists of relevant articles and reviews.
Study selection
Prospective studies (cohorts, follow-up of participants in randomised controlled trials, case-control nested within a cohort, and case-cohort) that reported a measure of association between pre-diagnosis circulating CRP concentrations in blood and subsequent risk of breast cancer development in women were selected.
Abstract review and selection was conducted in duplicate (DSMC, TN).
Data extraction
Study and population characteristics, biomarker assessment methods and sample type, CRP concentrations, number of breast cancer cases and population at-risk, and all relative risk (RR) estimates (hazard ratios and odds ratios) and the corresponding 95% confidence intervals (CI) or P-values, matching factors, confounder adjustments, and effect modifiers used in the studies were extracted.
Statistical analysis
Fixed-effect and random-effects dose-response meta-analyses were conducted. As there was evidence of heterogeneity between studies, only results from random-effects model that allows for possible variations of associations across the studies were reported. We used DerSimonian and Laird's method (24) to calculate the weighted average of the natural logarithm (ln) of the RRs of each study, and back-transformed using the exponential function. CRP was natural log-transformed to normalise data for analysis. The increment unit of the meta-analysis was per doubling (100% increase) of CRP concentration. For studies that reported a doseresponse slope per doubling of CRP concentration, we used the result directly. For studies that reported a dose-response slope per 1 ln unit increase, we re-scaled the result to per doubling of CRP concentration by raising the RR and 95% CI to the power of 0.693 [In (2) ]. For studies that only reported categorical data, we estimated the study-specific slope using generalised weighted least-squares regression model (25) based on the method of Greenland and Longnecker (26). In this method, adjusted log RRs are regressed on the exposure doses across the categories in a study, taking into account the correlation between risk estimates that are calculated using a common reference group. The method requires that the numbers of breast cancer cases and population at-risk for at least three categories of CRP concentrations and their means or medians values are provided. When the ranges of each category of CRP concentrations were instead reported, we assigned the corresponding RR to the midpoints of the category range. When the highest category was open-ended, we estimated the range using the width of the adjacent category. When the lowest category was open-ended, we used 0.1 mg/L as the lowermost concentration. Studies without the required data for the procedures were excluded from the analysis.
Maximally adjusted RRs reported in the papers were used in the meta-analyses. To assess heterogeneity between studies, we calculated the Cochran Q test (P h ) and I 2 statistic (%) (27). Sources of heterogeneity were explored in subgroups defined by number of cases, length of follow-up, publication year, study design, geographic location, CRP assessment method, and adjustments for confounders. To examine possible reverse causation, we restricted the studies into three groups based on exclusions of early years of follow-up as defined by the studies-studies with no exclusion of early years of follow-up; studies that reported a measure of association after the exclusion; and studies that reported no appreciably change of the estimates after the exclusion but did not show the results.
Egger's test and visual inspection of the funnel plot were performed to examine small study or publication bias (28). Each individual study was omitted in turn to examine the influence on the summary RR.
Furthermore, we examined the shape of the association using second order fractional polynomial models (29), including the studies with three or more categorical results and the required data for slope estimation as mentioned above. The fractional polynomial regression model with the lowest deviance was the best fitting model. Non-linearity was tested using the likelihood ratio test (30). 
Results

Results of search
Fifteen studies (16 publications) (17) (18) (19) (20) (21) (22) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) on CRP concentrations and breast cancer risk were identified in the literature search. Figure 1 shows the flowchart of search. Three studies (32, 36, 37) did not provide sufficient information to estimate a RR for each doubling of CRP concentration and could not be included in the meta-analysis (Supplementary Table S1 ). One study (32) reported a non-significant positive association when comparing CRP 6.5 with 0.4 mg/L. The result was attenuated with adjustment for BMI. Another study (36) reported a non-significant positive association per 3.2 mg/L increase of CRP concentration. BMI was accounted for in the study. The third study (37) reported a non-significant inverse association when comparing CRP ≥50.0 with <10 mg/L. The referent category in this study included low-grade inflammation, and may have resulted in an underestimation of the association between CRP and breast cancer (Supplementary Table S1 (40) reported a nonsignificant inverse association and the other study (22) reported a significant positive association with premenopausal breast cancer. Table 1 shows the characteristics and results of the prospective studies included in the present metaanalysis. There were one Asian study (22), five European studies (17, 21, 31, 33, 35) , and six American studies (18-20, 34, 38, 39) . In some studies, hormone therapy (HT) users ( Table 2 is a summary of the results from the dose-response meta-analyses. The studies included in each stratified analysis are listed in Supplementary Table S2 .
Study characteristics
Overall dose-response meta-analysis
Circulating CRP was statistically significantly positively associated with breast cancer risk ( Table 2 , Fig. 2 ).
The summary RR per doubling of CRP concentration was 1.07 (95% CI: 1.02-1.12). There was evidence of significant heterogeneity between studies (I 2 = 47%, P h = 0.04), which was partially explained by level of control for confounders. Studies that did not adjust for HT use, physical activity, or alcohol use reported on average stronger associations than studies adjusted for these factors. Positive associations although not always statistically significant were observed in most stratified analyses, with the exception of analyses restricted to studies that adjusted for physical activity and alcohol use. In the subgroup analyses by the exclusion of early years of follow-up in the studies, the summary RRs were significant in studies without the exclusion, slightly weaker in studies that reported no change in the estimates after the exclusion, and nonsignificant in studies with the exclusion. Summary estimates were of similar magnitude for studies that adjusted and not adjust for BMI (Table 2) .
Dose-response meta-analysis for post-menopausal breast cancer
For post-menopausal breast cancer, the summary RR per doubling of CRP concentration was 1.06 (95% CI:
1.01-1.11) when all nine studies (17-19, 22, 33-35, 38, 40) were combined (Table 2, Fig. 2 ). There was evidence of moderate heterogeneity between studies (I 2 = 32%, P h = 0.17), which was mostly explained by the Women's Health Study (WHS) (40) which had the biggest contribution (22% weight) in the analysis.
When the study was excluded, the summary RR was 1.08 (95% CI: 1.04-1.13) and I 2 reduced to 0% (P h = 0.52). The WHS was a follow-up of a randomised controlled trial evaluating the benefits and risks of lowdose aspirin and vitamin E in the primary prevention of cancer and cardiovascular disease in US female health professionals (39, 40) .
The significant positive association persisted in studies that excluded early years of follow-up, or reported no change of estimates after the exclusion. Similar positive associations were observed in the meta-analyses of studies that were adjusted or not adjusted for BMI ( Table 2 ). The summary RRs were 1.08 (95% CI: 1.03-1.13) for four studies not adjusted for BMI (17) (18) (19) 34 ) and 1.06 (95% CI: 1.00-1.12) for seven studies adjusted for BMI (18, 19, 22, 33, 35, 38, 40) . Moderate heterogeneity was only observed between studies that were adjusted for BMI (Not adjusted: I 2 = 0%, P h = 0.64; Adjusted: I 2 = 40%, P h = 0.13). Only two studies (18, 19) , both of post-menopausal women only, reported results for both models; when the two studies were combined, the summary RR was 1.07, 95% CI: 1.01-1.13 before adjustment for BMI and 1.06, 95% CI: 0.99-1.12 after adjustment (results not tabulated). As in the meta-analysis for overall breast cancer, no associations were observed in studies that adjusted for physical activity and alcohol use (Table 2) .
Three studies with data on postmenopausal women (17, 19, 40) investigated whether the association between circulating CRP and breast cancer risk varies according to BMI, and reported inconsistent results (Table 1) . One study (17) 
Other sensitivity analysis and test of publication bias
The summary RRs remained similar when each study was omitted in influence analyses including all studies or studies of post-menopausal women. Egger's tests showed some evidence of publication or small study bias (Overall: P = 0.08; Post-menopausal: P = 0.10). Visual inspection of the funnel plots showed that small studies with a null or weaker association than the average may be missing ( Supplementary Fig. S1 ).
Non-linear dose-response meta-analysis
In the analysis of all studies (any breast cancers), although the test for departure from linearity was statistically significant, the shape of the association was linear over most of the CRP range on the logarithmic scale [P non-linearity = 0.01; 10 studies (17-22, 31, 35, 38, 39)] (Fig. 3) . In post-menopausal women, the increase in risk was sharper and tailed off after 4 mg/L [P non-linearity < 0.001; 7 studies (17-19, 22, 35, 38, 40) ], probably because of the low number of points contributing to the analysis after this value, resulting in wide confidence intervals.
Discussion
By combining the current evidence from prospective studies of circulating CRP, a systemic low-grade inflammation biomarker, and breast cancer risk, 3,522 breast cancer cases and 2,516 post-menopausal breast cancer cases could be included in meta-analyses. Overall, we found a modest statistically significant positive association. For each doubling (100% increase) of CRP concentration, there was a 7% increase in breast cancer risk and a 6% increase in post-menopausal breast cancer risk. The relationship was linear on the logarithmic scale. The observed association with circulating CRP was also present in studies that examined reverse causation by excluding cases diagnosed in early years of follow-up. Our meta-analysis is consistent with a recently published meta-analysis that showed an inverse negative association between NSAIDs use and breast cancer risk (summary RR = 0.97, 95% CI: 0.94-1.00; I 2 = 88%, P h <0.001; 12 cohort studies) (41) . However, the few studies that examined genotypes that influence CRP levels in blood and breast cancer risk did not offer consistent results (20, [42] [43] [44] [45] . The elevated CRP could be a marker of host response to early malignancy or disease progression instead of a causal factor for breast cancer development. Our results therefore need to be confirmed in future studies.
A number of limitations should be considered when interpreting our findings. Seven out of 12 studies included in the overall analysis were of post-menopausal women only (17-19, 33-35, 38) . Thus premenopausal women were underrepresented in the present review. Significant heterogeneity existed in the overall meta-analysis. Differences in the level of control for confounding in the studies may partly explain the heterogeneity, but the evidence provided by the meta-analysis is limited by the low number of studies in the subgroup analyses. Also, the studies included in the subgroups are different, which hinder direct comparisons between the results. On average, the associations in studies that were unadjusted for HT use, physical activity, or alcohol use appeared stronger compared with adjusted results. Similar significant associations were observed in the studies adjusted or not adjusted for BMI. However, direct comparison was only possible in two studies of post-menopausal women that reported multivariable results from both models adjusted and not adjusted for BMI (18, 19) , and the results were slightly attenuated after adjustment for BMI.
The association could also be mediated or modified by body adiposity, but the data were limited and equivocal (17, 19, 40) .
Another limitation is that some studies could not be included in the meta-analyses because of insufficient data (32, 36, 37). If included, the summary association would have been weakened by one large study (1,241 cases) (37) which reported a possibly underestimated (non-significant inverse) association of CRP that was detected by a conventional assay. Other excluded studies (32, 36) reported results similar to those included in the meta-analysis. Funnel plots showed that small studies with a null or weaker association than the average estimated in this meta-analysis may be missing. However, as our search included the major sources for searching related literature [MEDLINE using the platform of PubMed and the reference lists of related publications (46) ], it is unlikely that we missed publications in our review.
Although CRP concentrations have good consistency over time (47, 48) , the studies included in the review only performed one CRP assessment at study baseline and some misclassification cannot be excluded, possibly leading to attenuation of association. 
